Last $0.39 USD
Change Today -0.0232 / -5.66%
Volume 63.2K
RGDX On Other Exchanges
As of 3:16 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

response genetics inc (RGDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - $1.73
52 Week Low
12/16/14 - $0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESPONSE GENETICS INC (RGDX)

Related News

No related news articles were found.

response genetics inc (RGDX) Related Businessweek News

No Related Businessweek News Found

response genetics inc (RGDX) Details

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples. The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites. It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

109 Employees
Last Reported Date: 03/31/14
Founded in 1999

response genetics inc (RGDX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.7K
Vice President of Research & Development
Total Annual Compensation: $333.5K
Compensation as of Fiscal Year 2013.

response genetics inc (RGDX) Key Developments

Response Genetics, Inc. Secures New York State Department of Health Approval for its ResponseDX(R) Testing Services

Response Genetics Inc. received approval from the New York State Department of Health to offer, market and report results of the Company's ResponseDX® tests to healthcare providers in the State of New York. The State of New York is the third most populated state in the U.S. and the addition of this license should contribute to the continued growth of the Company's ResponseDX® sales in 2015.

Response Genetics Receives Non-Compliance Notice From Nasdaq

On November 24, 2014, Response Genetics, Inc. received a notice letter from the staff of The NASDAQ Stock Market LLC (Nasdaq) providing notification that, based on the Company’s stockholders’ equity of $2,009,700 disclosed in the Company’s Form 10-Q for the period ended September 30, 2014 (filed with the Securities and Exchange Commission on November 14, 2014), the Company does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, set forth in Listing Rule 5550(b)(1). Under applicable Nasdaq requirements, the Company has 45 calendar days to submit a plan to regain compliance with the Rule. The Company is working on a plan for submission to Nasdaq which the Company believes will enable it to regain compliance with the Rule. The Company intends to provide Nasdaq with such a plan on or before the January 8, 2015 deadline. If the plan is accepted, Nasdaq can grant the Company an extension of up to 180 calendar days from November 24, 2014 to evidence compliance.

Response Genetics, Inc Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Response Genetics Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenue was $4,092,277 compared to $4,464,991 for the same period a year ago. Operating loss was $2,737,287 compared to $3,354,485 for the same period a year ago. Net loss was $2,718,126 or $0.08 per basic and diluted share compared to $3,643,946 or $0.09 per basic and diluted share for the same period a year ago. The increase in total revenue was from higher ResponseDX sales offset by lower pharmaceutical client revenue, which can vary significantly on a quarterly basis by its very nature and concentration. For the nine months, the company reported net revenue was $15,030,382 compared to $12,641,160 for the same period a year ago. Operating loss was $4,794,185 compared to $9,939,803 for the same period a year ago. Net loss was $4,839,585 or $0.15 per basic and diluted share compared to $10,287,300 or $0.27 per basic and diluted share for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.39 USD -0.0232

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $6.61 USD +0.3201
Foundation Medicine Inc $21.52 USD +0.79
NeoGenomics Inc $4.15 USD +0.02
Rosetta Genomics Ltd $2.32 USD +0.04
Veracyte Inc $7.62 USD +0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at